Jonathan Berlent has been appointed vice president of business development at Tris Pharma. He will lead the company’s product and technology partnering, and collaborate with branded pharmaceutical companies on their life cycle management opportunities.
“As Tris scales up its effort to address the growing unmet need in the industry for liquid extended release technology, Jonathan will lead business development efforts and be our point person with branded pharmaceutical companies,” said Ketan Mehta, president and chief executive officer of Tris Pharma.
Mr. Berlent has a combination of pharmaceutical and securities industry experience. For the past nine years, he has held various senior leadership positions in the pharmaceutical industry. Most recently, he was president of Granules USA, where he led its North American operations and successfully launched a finished dosage business platform, working with companies including Pfizer, Novartis, McNeil Consumer Health Janssen, GlaxoSmithKline, Par and Perrigo.